PharmaCyte Biotech, Inc.
pharmacytebiotech.comAI Executive Summary
AI-powered analysis of 10-Q filing content
PharmaCyte shows severe financial deterioration with zero revenue, massive warrant liability increases to $13.7M (from $338K), accumulated deficit growing to $100M, and substantial dilution through Series C preferred stock issuance. The company remains entirely pre-revenue with volatile fair value adjustments driving financial results.
Red Flags Detected (7)
Zero revenue with $4.3M operating expenses in 9 months
Warrant liabilities exploded 4,043% to $13.7M from $338K
Accumulated deficit increased $15M to $100M
4 more red flags detected
Key Takeaways
Company remains entirely pre-revenue biotechnology firm with significant cash burn
Complex warrant and derivative structures create substantial balance sheet volatility
2 more takeaways
Filing Overview
What This Means
Deteriorating Trend: Conditions are worsening compared to previous filings. This may create opportunities for service providers.
Quarterly Report: Interim filing with unaudited financial data for the quarter.